Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment: Annals of the New York Academy of Sciences

Annals of the New York Academy of Sciences

Volumn 1193, Issue , 2010, Pages 15-21

  Cutolo, Maurizio ^a   Villaggio, Barbara ^a   Pizzorni, Carmen ^a   Paolino, Sabrina ^a   Moretti, Stefano ^b   Gallo, Fabio ^b   Bonassi, Stefano ^c   Sulli, Alberto ^a   Seriolo, Bruno ^a   Montagna, Paola ^a   Soldano, Stefano ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Early arthritis; Gene microarray; Glucocorticoids; Inflammation; Leflunomide; Rheumatoid arthritis

Indexed keywords

CALGRANULIN B; CD2 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; L SELECTIN; LEFLUNOMIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PEROXIREDOXIN; PHOSPHOTRANSFERASE; PREDNISONE; SOMATOMEDIN BINDING PROTEIN 3; STAT4 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2; VASCULOTROPIN B;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MICROARRAY ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; RHEUMATOID ARTHRITIS; RNA EXTRACTION; TREATMENT DURATION; UPREGULATION;

EID: 77951225001     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05297.x     Document Type: Conference Paper

References (25)

1. Klareskog, L., A.I. Catrina & S. Paget. 2009. Rheumatoid arthritis. Lancet 373: 659-672.
2. Buttgereit, F., G. Burmester & J.W. Bijlsma. 2007. Disease-modifying effects of glucocorticoids in rheumatoid arthritis] Kommission Pharmakotherapie der DGRh. Z Rheumatol. 66: 522-524.
3. Guidelines for the Management of Rheumatoid Arthritis. ACR Subcommittee. 2002. Arthrit Rheum. 46: 328-332.
4. Dayer, J.M. & M. Cutolo. 2005. Is there a rationale to using leflunomide in early rheumatoid arthritis? Clin. Exp. Rheumatol. 23: 404-412.
5. Cutolo, M., A. Sulli, P. Ghiorzo, et al. 2003. Antiinflammatory effects of leflunomide oncultured synovial macrophages from patients with rheumatoid arthritis. Ann. Rheum. Dis. 62: 297-302.
6. MacGregor, A.J., H. Snieder, A.S. Rigby, et al. 2000. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43: 30-37.
7. Laivoranta-Nyman, S., T. Mottonen, P. Hannonen, et al. 2006. Association of tumor necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis. Clin. Exp. Rheumatol. 24: 636-642.
8. Toonen, E.J., P. Barrera, T.R. Radstake, et al. 2008. Gene expression profiling in rheumatoid arthritis: current concepts and future directions. Ann. Rheum. Dis. 67: 1663-1669.
9. R Development Core Team. 2008. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. ISBN 3-90051-070:1-1679.
10. Ward, J.H. 1963. Hierarchical grouping to optimize an objective function. J. Am. Stat. Assoc. 58: 236-244.
11. Fisher, R.A. 1935. The logic of inductive inference. J Royal Statist Soc Series A 98: 39-54.
12. O'Mahony, R. et al. 2009. Withdrawal of DMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 17. doi:10.1136/ard.2008.105577. Epub ahead of print.
13. Kaizuka, Y., A.D. Douglass, S. Vardhana, et al. 2009. The coreceptor CD2 uses plasma membrane microdomains to transduce signals in T cells. J. Cell. Biol. 185: 521-534.
14. Unterberger,C., K.J. Staples, T. Smallie, et al. 2008. Role of STAT3 in glucocorticoid-induced expression of the human IL-10 gene. Mol. Immunol. 45: 3230-3237.
15. Taylor, A., J. Verhagen, T. Akkoc, et al. 2009. IL-10 suppresses CD2-mediated T cell activation via SHP-1. Mol. Immunol. 46: 622-629.
16. Bissonnette, R. et al. 2009. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.Arch.Dermatol. Res. 2009; 301: 429-442.
17. O'Neill, S.K., Y. Cao, K.M.Hamel, et al. 2007. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J. Immunol. 179: 5109-5116.
18. Buch,M.H., E.M. Vital&P. Emery. et al. 2008. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res. Ther. 10(Suppl 1): S5. (doi:10.1186/ar2416).
19. Schett, G., M. Tohidast-Akrad, J.S. Smolen, et al. 2000. Activation, differential localization, and regulation of the stress-activated kinases, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 mitogen activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 43: 2501-2512.
20. Han, Z. et al. 2001. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. Clin. Invest. 108: 181-183.
21. Remmers, E.F., R.M. Plenge, A.T. Lee, et al. 2007. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357: 977-986.
22. Winner, M., A.C. Koong, B.E. Rendon, et al. 2007. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxiainducible factor stabilization. Cancer Res. 67: 186-193.
23. Khong, T.L.,H. Larsen, Y. Raatz & E. Paleolog. 2007. Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. Angiogenesis. 10: 243-258.
24. Giatromanolaki, A., E. Sivridis, E. Maltezos, et al. 2003. Upregulated hypoxia inducible factor-1alpha and -2alphapathway in rheumatoid arthritis and osteoarthritis. Arthritis Res. Ther. 5: R193-R201.
25. Lim, S.Y. et al. 2009. Oxidative modifications of S100 proteins: functional regulation by redox. J. Leukoc. Biol. 2009; 86: 577-587.